What's hot

View all perspectives
What's Hot

JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay

Watch video →

RheumNow Rheumatology Roundup: Drs. Kavanaugh and Cush

Rheumatology Roundup! Drs. Cush and Kavanaugh convene for their annual impromptu review of some of the best and more interesting abstracts presented at ACR 2021.    

Watch video →

TNF Inhibitor Panel Discussion: ACR21 Annual Meeting

RheumNow TNFi faculty convened to discuss several TNFi-related abstracts presented at ACR 21. Panelists: Drs. Aurelie Najm, Janet Pope, David Liew, Eric Dein and Swetha Alexander. 

Watch video →

Spondyloarthritis Panel Discussion: ACR21 Meeting

Panelists: Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood. Abstracts discussed include #0562, #1919, #0907, #0364 and #0919

Watch video →

Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay

Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.

Watch video →

Diagnosing (Bad) VEXAS: The Experts Speak Drs. Beck and Ferrada

Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting.

Watch video →

Pediatric Psoriatic Arthritis: Dr. Eric Ruderman

Dr. Ruderman discusses abstracts #1424 presented at the ACR21 annual meeting.

Watch video →

Urine Proteome Advances: What Do They Mean? Dr. Michelle Petri

Dr. Petri reviews abstracts #1422 and #1936, presented at the ACR21 annual meeting.

Watch video →

ACR21 Day 3 Recap: Polypharmacy, New Lupus Drugs, VEXAS, Safety Data

Blurb: Drs. Jack Cush and the RheumNow Faculty Drs. Akhil Sood, Antoni Chan, Olga Petryna and Eric Dein, discuss highlights from Day 3 (Monday) at the ACR21 annual meeting. Abstracts include #1367, #1044, #1444, #1083 and more.

Watch video →

Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles

Dr. Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.

Watch video →

Predictors of TNF Response with Drs. Pope, Dein and Liew

Drs. Janet Pope, David Liew and Eric Dein discuss TNF data presented at the ACR21 annual meeting, including abstracts #1251, #1442, #1448.

Watch video →

Caring for the Older Patient with Rheumatic Disease: Drs. Makris, Yung and Dao

Drs. Kathryn Dao, Una Makris and Raymond Yung discuss the field of geriatric rheumatology and caring for the older patient with rheumatic disease.

Watch video →

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares

  Drs. Jack Cush, Yuz Yusof, Bella Mehta, Olga Petryna and Rachel Tate review autoinflammatory data presented at the ACR21 annual meeting, including abstracts #1100, #1062, #1426, #0252, #0195, and #1083.

Watch video →

FDA Session Review: Dr. Arthur Kavanaugh

Dr. Kavanaugh discussed the FDA session presented at the ACR21 annual meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.

Watch video →

The Respiratory Tract and RA with Drs. Sparks, McDermott and Kronzer

Drs. Jeffrey Sparks, Greg McDermott and Vanessa Kronzer discuss work in the area of respiratory disease in RA, mucosal paradigm, RA-ILD, bronchiectasis, as well as their experience as virtual attendees at the ACR21 annual meeting.

Watch video →

Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush

Dr. Cush reviews poster #1100 presented at the ACR21 annual meeting.

Watch video →

Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri

Dr. Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the ACR21 annual meeting.

Watch video →

ACR21 Day 2 Recap: CV Risk, Tapering in SpA, Microbiome in PsA, Vit D

Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 (Sunday) at the ACR21 Virtual meeting.

Watch video →
      RT @RHEUMarampa: Promising results of Risankizumab for #psoriaticarthritis
      🔸Pts significantly achieved higher rates

      sheila RHEUMarampa

      4 years ago
      Promising results of Risankizumab for #psoriaticarthritis 🔸Pts significantly achieved higher rates of ACR20, 50 and 70 response at wk 24 vs. placebo 🔸Well tolerated and showed no safety signals @RheumNow #ACR21 #ACRBest abs0453 https://t.co/TDSLEgF68g
      RT @swethaann23: #ACR21 @RheumNow
      Abst#0450 Hwang et al. from the PSOAS cohort analyzed 1618 radiographs between 2002-2

      swethaann23 swethaann23

      4 years ago
      #ACR21 @RheumNow Abst#0450 Hwang et al. from the PSOAS cohort analyzed 1618 radiographs between 2002-2017 ⭐️Higher spinal disease: Male gender; longer disease duration; smoking ⭐️🔼Disease progression 🔼CRP levels ⭐️🔽Disease progression with time-varying TNFI use https://t.co/XsKp28HOxz
      RT @AurelieRheumo: Pre clinical RA: don't miss the feet 🦶🏼! Among 577 patients
      with clinically suspect arthralgia

      Aurelie Najm AurelieRheumo

      4 years ago
      Pre clinical RA: don't miss the feet 🦶🏼! Among 577 patients with clinically suspect arthralgia undergoing MRI: -23% intermetatarsal bursitis > ACPA + 56% vs. 19% -higher risk or RA HR 3.3. Would we find the same results w/ US? #OP0468 @RheumNow #ACR2021 https://t.co/VkzUu93qGq https://t.co/GGw7UgdPVR
      RT @RHEUMarampa: Accdg to this study by Dr. B VanDijk et al, intermetatarsal bursitis (IMB) was seen in 23% of clin susp

      sheila RHEUMarampa

      4 years ago
      Accdg to this study by Dr. B VanDijk et al, intermetatarsal bursitis (IMB) was seen in 23% of clin suspect arthralgia(CSA) pts; predicted clinical arthritis in ACPA+; ⬆ frequent w/ synovitis & tenosynovitis Addtl tool for early RA dx? @RheumNow #ACR21 abs0468 #ACRBest https://t.co/bcUuy8bHLJ
      RT @doctorRBC: AxSpA pts share a gut microbiome signature with Crohn's disease and anterior uveitis pts
      ⬇️Blautia
      â¬

      Robert B Chao, MD doctorRBC

      4 years ago
      AxSpA pts share a gut microbiome signature with Crohn's disease and anterior uveitis pts ⬇️Blautia ⬆️Veillonella and Lactobacillus ⭐️SpA pts uniquely enriched in Collinsella Abs#0062 #ACR21 @RheumNow #ACRBest https://t.co/sdlHxNbhr8 https://t.co/r8eG9c9vwa
      RT @uptoTate: Early axSpA DESIR: higher dz activity & worse function independently assoc'd w/ ^ hazard of Work Disab

      Dr. Rachel Tate uptoTate

      4 years ago
      Early axSpA DESIR: higher dz activity & worse function independently assoc'd w/ ^ hazard of Work Disability vs SES. Dz severity strong predictor of adverse work outcome despite advanced therapeutic strategies in axSpA. Abs 0381 #ACR21 #RheumNow @RheumNow https://t.co/Lc3yUgXvw6
      RT @ericdeinmd: #ACR21 Abst#0455 ARIAA Study: Abatacept for subclinical arthritis
      ⭐️ ACPA + arthralgia + MRI inflamm

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abst#0455 ARIAA Study: Abatacept for subclinical arthritis ⭐️ ACPA + arthralgia + MRI inflammation 🔥 ⭐️ ⬇️ MRI inflam (primary) and ⬇️ progression to arthritis (secondary) ▶️ Many patients likely early RA, would still rec starting MTX 1st https://t.co/4aREvqlpUI @Rheumnow https://t.co/vqRgsd75Il
      RT @MeralElRamahiMD: #ACR21 Abst#0293:
      Lung involvement in 67 sero+ RA pts assoc w/:
      ⭐︎ SSc-specific ab
      ➡️ RP1

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      #ACR21 Abst#0293: Lung involvement in 67 sero+ RA pts assoc w/: ⭐︎ SSc-specific ab ➡️ RP155, Th/To, fibrillarin, NOR90 in ILD group ➡️ Ku, Pm/Scl100, CENP-A/B in non-ILD group ⭐︎ older age, ⚦ sex, heavy 🚬 ⭐︎ ↑ WBC, CRP, RF #ACRBest @Rheumnow https://t.co/Yo4jRKqvfV https://t.co/l5gbKoZBkm
      RT @KDAO2011: Yikes! Higher rates of lupus nephritis deaths in last 5 years
      👉8900 lupus nephritis deaths in USA studi

      TheDaoIndex KDAO2011

      4 years ago
      Yikes! Higher rates of lupus nephritis deaths in last 5 years 👉8900 lupus nephritis deaths in USA studied race/ethnicity and urbanization assc w/ LN mortality 👉highest in blacks and large central metro regions #ACR21 #Plenary Abstr# 0454 @rheumnow https://t.co/bxQvID8jht
      RT @RHEUMarampa: Nice graphic presentation of the results! Dr. Katie Liao and her group present the characteristics and

      sheila RHEUMarampa

      4 years ago
      Nice graphic presentation of the results! Dr. Katie Liao and her group present the characteristics and disease manifestations of Ro+ #SLE patients from the Australian #lupus registry and biobank @RheumNow #ACR21 abs0323 https://t.co/Yl5sZgiTw1
      RT @RichardPAConway: ARIAA study of abatacept in pre-RA. Abatacept ⬇️MRI inflammation and reduces progression to RA.

      Richard Conway RichardPAConway

      4 years ago
      ARIAA study of abatacept in pre-RA. Abatacept ⬇️MRI inflammation and reduces progression to RA. Of course it does. Like all these studies, really not sure what this is telling us. Abstr#0455 #ACR21 @RheumNow https://t.co/yNVVZFBWDq
      RT @doctorRBC: Is it time to consider targeting gut microbiome for treatment of AS?
      Large study identified:
      ⭐️Rumino

      Robert B Chao, MD doctorRBC

      4 years ago
      Is it time to consider targeting gut microbiome for treatment of AS? Large study identified: ⭐️Ruminococcus torques associated with FUT2 gene influences risk of developing AS Abs#0068 https://t.co/E1hL18KZbQ #ACR21 #ACRBest @RheumNow
      RT @Yuz6Yusof: #ACR21 #Abstr0454 Mortality rate in #lupus nephritis ⬇️by 26% from 1999-2019👏. BUT, racial and res

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years ago
      #ACR21 #Abstr0454 Mortality rate in #lupus nephritis ⬇️by 26% from 1999-2019👏. BUT, racial and residence disparities were concerning; worse in Black, Hispanic, Asian, AI/AN vs White and in large central and medium metro. Residential matters! @RheumNow https://t.co/33vN39acuL https://t.co/XMwN2hXJn7
      RT @uptoTate: Possible disease activity biomarkers in axSpA? Neutrophil lymphocyte ratio (NLR) & platelet lymphocyte

      Dr. Rachel Tate uptoTate

      4 years ago
      Possible disease activity biomarkers in axSpA? Neutrophil lymphocyte ratio (NLR) & platelet lymphocyte ratio (PLR) along w/ PROs may be helpful to measure dz activity clinically. More studies needed for proof of concept. Abs 0384 #ACR21 #RheumNow @RheumNow https://t.co/ZXyQHNzqz7 https://t.co/va5fBR9Gnk
      RT @swethaann23: #ACR21 @RheumNow
      Abst#0370 by Afinogenova et al.
      138 PCP surveyed on Chronic back pain evaluation

      â

      swethaann23 swethaann23

      4 years ago
      #ACR21 @RheumNow Abst#0370 by Afinogenova et al. 138 PCP surveyed on Chronic back pain evaluation ▶️58% rarely assess for IBP ▶️40% not comfortable diagnosing AS ▶️70% not comfortable diagnosing axSpA Contributing to a lack of referral to rheumatology and delay in diagnosis.

      Podcasts

      • Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie 00:20:18
      • Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao 00:20:26
      • The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell 00:35:26

      Catch up on Conference Podcasts

      ×